Location: Canada, Ontario, London
Total raised: $14.2M
Investors 2
| Date | Name | Website |
| 29.01.2023 | Bantam Gro... | bantamgrou... |
| - | Esperante | esperante.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.12.2022 | Grant | $14.2M | - |
Mentions in press and media 19
| Date | Title | Description | Source |
| 24.11.2022 | LumiraDx Launches Rapid Microfluidic Immunoassay C-Reactive ... | Mumbai, Maharashtra, India The LumiraDx CRP diagnostic test combines speed and test sensitivity at ... | newsvoir.c... |
| 15.11.2022 | Using Point of Care Testing to Transform Patient Care in Gen... | With the National Health Service (NHS) committing to a target of becoming net zero by 2045³, the spe... | prweb.com/... |
| 14.11.2022 | LumiraDx Continues Commercial Expansion of its Rapid Microfl... | Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa Early customers i... | en.prnasia... |
| 09.11.2022 | Supporting Antimicrobial Stewardship Using Point of Care CRP... | Tackling AMR requires a multi-faceted approach and research has shown how incorporating CRP (C-react... | prweb.com/... |
| 29.07.2022 | Transforming Point-of-Care Diagnostic Testing, Upcoming Webi... | Next-generation POC testing, different from traditional lateral flow tests, is proving its ability t... | prweb.com/... |
| 14.01.2022 | LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Det... | Results from ongoing testing and monitoring of COVID-19 variants shows the rapid microfluidic test d... | en.prnasia... |
| 27.12.2021 | DIGIT’s Biggest Scottish Deals of 2021 | Despite a difficult two years due to the pandemic and the impact of Brexit, Scottish companies have ... | digit.fyi/... |
| 10.11.2021 | LumiraDx Reports Third Quarter 2021 Financial Results | LONDON, Nov. 10, 2021 /PRNewswire/ -- LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) ... | marketscre... |
| 20.10.2021 | LumiraDx : receives approval for its COVID-19 Antigen Test f... | LONDON, Oct. 20, 2021 /PRNewswire/ -- Today, LumiraDx (Nasdaq: LMDX), a next-generation point of car... | marketscre... |
| 20.10.2021 | LumiraDx Receives Approval for its COVID-19 Antigen Test for... | London, United Kingdom Test combines sensitivity with speed and is designed to be used in health ca... | newsvoir.c... |
Show more